株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

嚢胞性線維症:パイプライン製品の分析

Cystic Fibrosis - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 232829
出版日 ページ情報 英文 383 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.00円で換算しております。
Back to Top
嚢胞性線維症:パイプライン製品の分析 Cystic Fibrosis - Pipeline Review, H1 2017
出版日: 2017年05月09日 ページ情報: 英文 383 Pages
概要

嚢胞性線維症は、粘液および発汗、消化液を生成する細胞に作用する遺伝性疾患です。その症状は喘鳴、息切れ、度重なる肺感染症、鼻腔の炎症、重度の便秘などがあります。嚢胞性線維症に罹患には遺伝的要因、人種(北欧圏の白人に多い)が深くかかわっていると言われています。治療には抗菌薬、濃性粘液の分解薬、気管支拡張薬、経口の膵酵素剤などを利用します。

当レポートでは、嚢胞性線維症治療薬の開発状況について調査しており、パイプライン製品の概要、治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

嚢胞性線維症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

嚢胞性線維症:企業で開発中の治療薬

嚢胞性線維症:大学/機関で研究中の治療薬

嚢胞性線維症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

嚢胞性線維症:企業で開発中の製品

嚢胞性線維症:大学/機関で研究中の製品

嚢胞性線維症の治療薬開発に従事している企業

  • Actelion Ltd
  • Akari Therapeutics, Plc
  • Alaxia SAS
  • AlgiPharma AS
  • AmpliPhi Biosciences Corporation
  • Arcturus Therapeutics, Inc
  • Aridis Pharmaceuticals LLC
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Calista Therapeutics, Inc.
  • Carolus Therapeutics, Inc.
  • Celtaxsys, Inc.
  • Chiesi Farmaceutici SpA
  • Cilian AG
  • Concert Pharmaceuticals, Inc.
  • Corbus pharmaceuticals, Inc.
  • CSA Biotechnologies LLC
  • Cyclacel Pharmaceuticals, Inc.
  • DiscoveryBiomed, Inc.
  • Editas Medicine, Inc.
  • Errant Gene Therapeutics, LLC
  • Galapagos NV
  • GlaxoSmithKline Plc
  • Grifols, S.A.
  • Grupo Praxis Pharmaceutical SA
  • Horizon Pharma Plc
  • Insmed Incorporated
  • Invion Limited
  • JHL Biotech, Inc.
  • Kamada Ltd.
  • La Jolla Pharmaceutical Company
  • Lamellar Biomedical Ltd
  • Laurent Pharmaceuticals Inc.
  • Mast Therapeutics, Inc.
  • Merck & Co., Inc.
  • Microbion Corporation
  • Mucokinetica Ltd.
  • NanoBio Corporation
  • Nivalis Therapeutics, Inc.
  • Nostrum Pharmaceuticals, LLC
  • Novabiotics Limited
  • Novartis AG
  • OSE Pharma SA
  • Parion Sciences, Inc.
  • Pfizer Inc.
  • Pharmaxis Limited
  • PhaseBio Pharmaceuticals, Inc.
  • Polyphor Ltd.
  • Progenra, Inc.
  • ProMetic Life Sciences Inc.
  • ProQR Therapeutics N.V.
  • Protalix BioTherapeutics, Inc.
  • Proteostasis Therapeutics, Inc.
  • PTC Therapeutics, Inc.
  • Pulmatrix, Inc.
  • Raptor Pharmaceutical Corp.
  • ReveraGen BioPharma, Inc.
  • Savara Inc.
  • Serendex Pharmaceuticals A/S
  • Shionogi & Co., Ltd.
  • Shire Plc
  • Synovo GmbH
  • TGV-Laboratories
  • The International Biotechnology Center (IBC) Generium
  • Verona Pharma Plc
  • Vertex Pharmaceuticals Incorporated
  • Xenetic Biosciences (UK) Limited
  • Zambon Company S.p.A.

嚢胞性線維症:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (ammonium chloride + citric acid + sodium citrate)
  • (fosfomycin + tobramycin)
  • (ivacaftor + tezacaftor)
  • ABPA1
  • acebilustat
  • Aerucin
  • alpha proteinase inhibitor (human) second generation
  • ALX09
  • amikacin sulphate
  • amlexanox
  • Anti-Pseudomonas IgY
  • Antimicrobial Drug for Cystic Fibrosis
  • AT10
  • ataluren
  • AZD634
  • BI43651
  • Biologics for Cystic Fibrosis Lung Infections
  • Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis
  • Brevenal
  • Calcaftor
  • CFX
  • CSA3
  • CSY073
  • CT009
  • CTP56
  • cysteamine IR
  • dapsone
  • Deoxyribonuclease II to Inhibit DNA Synthesis for Cystic Fibrosis
  • doripenem
  • dornase alfa biosimilar
  • dornase alfa biosimilar
  • Drugs for Cystic Fibrosis
  • FDL69
  • fenretinide
  • Gene Therapy to Activate CFTR for Cystic Fibrosis
  • Gene Therapy to Activate CFTR for Cystic Fibrosis
  • Gene Therapy to Activate CFTR Gene for Cystic Fibrosis
  • GLPG837
  • GLPG837 + GLPG222 + GLPG665
  • GLPG222
  • GLPG451
  • GLPG665
  • GLPG737
  • GLPG851
  • glycerol phenylbutyrate
  • GSK225745
  • itraconazole
  • JBT01
  • kenpaullone
  • levofloxacin
  • levofloxacin
  • LJPC0Sa
  • LJPC0Sb
  • LMS11
  • LUNAR-CF
  • mannitol
  • MBN01
  • MG77
  • miglustat
  • MKA04
  • molgramostim
  • Mul867
  • N1115
  • N1138
  • N1169
  • nadolol
  • NB01
  • nitric oxide
  • nitric oxide
  • Nu
  • NVPQBE70
  • Oligomer G for Cystic Fibrosis
  • ORP00
  • P055
  • PAC-IC
  • Panaecin
  • PB1
  • PB046
  • PB120
  • PBI050
  • POL014
  • PRX10
  • PTI30
  • PTI28
  • PTIC811
  • PTIP71
  • PulmoXen
  • PXS728A
  • QR10
  • QRX
  • Recombinant A1PI
  • Recombinant Acid Ceramidase Replacement for Farber Disease and Cystic Fibrosis
  • Recombinant Enzyme to Target DNA for Cystic Fibrosis
  • Recombinant Protein for Infectious Diseases and Respiratory Disorders
  • riociguat
  • RPL54
  • S226
  • S229
  • S8
  • seliciclib
  • SHP37
  • Small Molecule for Cystic Fibrosis
  • Small Molecule for Pneumonia, COPD, Cystic Fibrosis and Pulmonary Tuberculosis
  • Small Molecule to Activate CFTR for Cystic Fibrosis
  • Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease
  • Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD
  • Small Molecules for Bacterial Infections
  • Small Molecules for Bacterial Infections, Oncology and Cystic Fibrosis
  • Small Molecules for Cystic Fibrosis
  • Small Molecules to Activate CFTR for Cystic Fibrosis
  • Small Molecules to Activate CFTR Protein for Cystic Fibrosis
  • Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis
  • Small Molecules to Agonize PPAR-Gamma for COPD and Cystic Fibrosis
  • Small Molecules to Block SCNN1 for Cystic Fibrosis
  • Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis
  • Small Molecules to Inhibit USP8 for Cystic Fibrosis
  • sodium nitrite
  • solithromycin
  • SP4
  • SP
  • Stem Cell Therapy for Cystic Fibrosis
  • SYGN13
  • SYGN03
  • tritoqualine
  • vamorolone
  • vancomycin hydrochloride
  • VX52
  • VX71
  • VX40
  • ZP46

嚢胞性線維症:最近のパイプライン動向

嚢胞性線維症:休止中のプロジェクト

嚢胞性線維症:開発が中止された製品

嚢胞性線維症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9218IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis - Pipeline Review, H1 2017, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.

Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body's organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 5, 25, 27, 1, 55, 25 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical, Discovery and Unknown stages comprises 2, 4, 7 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Cystic Fibrosis - Overview
  • Cystic Fibrosis - Therapeutics Development
  • Cystic Fibrosis - Therapeutics Assessment
  • Cystic Fibrosis - Companies Involved in Therapeutics Development
  • Cystic Fibrosis - Drug Profiles
  • Cystic Fibrosis - Dormant Projects
  • Cystic Fibrosis - Discontinued Products
  • Cystic Fibrosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Cystic Fibrosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Cystic Fibrosis - Pipeline by Achaogen Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Actelion Ltd, H1 2017
  • Cystic Fibrosis - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H1 2017
  • Cystic Fibrosis - Pipeline by Aeolus Pharmaceuticals Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Alaxia SAS, H1 2017
  • Cystic Fibrosis - Pipeline by AlgiPharma AS, H1 2017
  • Cystic Fibrosis - Pipeline by AmpliPhi Biosciences Corp, H1 2017
  • Cystic Fibrosis - Pipeline by Apteeus, H1 2017
  • Cystic Fibrosis - Pipeline by Arch Biopartners Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Arcturus Therapeutics Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
  • Cystic Fibrosis - Pipeline by AstraZeneca Plc, H1 2017
  • Cystic Fibrosis - Pipeline by Bayer AG, H1 2017
  • Cystic Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Cystic Fibrosis - Pipeline by Catabasis Pharmaceuticals Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Celtaxsys Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H1 2017
  • Cystic Fibrosis - Pipeline by Cilian AG, H1 2017
  • Cystic Fibrosis - Pipeline by Concert Pharmaceuticals Inc, H1 2017
  • Cystic Fibrosis - Pipeline by CRISPR Therapeutics, H1 2017
  • Cystic Fibrosis - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
  • Cystic Fibrosis - Pipeline by DiscoveryBiomed Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Editas Medicine Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Eloxx Pharmaceuticals Ltd, H1 2017
  • Cystic Fibrosis - Pipeline by Enterprise Therapeutics Ltd, H1 2017
  • Cystic Fibrosis - Pipeline by Errant Gene Therapeutics LLC, H1 2017
  • Cystic Fibrosis - Pipeline by ethris GmbH, H1 2017
  • Cystic Fibrosis - Pipeline by Galapagos NV, H1 2017
  • Cystic Fibrosis - Pipeline by Gilead Sciences Inc, H1 2017
  • Cystic Fibrosis - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Cystic Fibrosis - Pipeline by Grifols SA, H1 2017
  • Cystic Fibrosis - Pipeline by Grupo Praxis Pharmaceutical SA, H1 2017
  • Cystic Fibrosis - Pipeline by Horizon Pharma Plc, H1 2017
  • Cystic Fibrosis - Pipeline by ID Pharma Co Ltd, H1 2017
  • Cystic Fibrosis - Pipeline by Immun System IMS AB, H1 2017
  • Cystic Fibrosis - Pipeline by Insmed Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Invion Ltd, H1 2017
  • Cystic Fibrosis - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
  • Cystic Fibrosis - Pipeline by JHL Biotech Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Kamada Ltd, H1 2017
  • Cystic Fibrosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
  • Cystic Fibrosis - Pipeline by La Jolla Pharmaceutical Company, H1 2017
  • Cystic Fibrosis - Pipeline by Lakewood-Amedex Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Lamellar Biomedical Ltd, H1 2017
  • Cystic Fibrosis - Pipeline by Laurent Pharmaceuticals Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Mast Therapeutics Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Merck & Co Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Microbion Corp, H1 2017
  • Cystic Fibrosis - Pipeline by Mucokinetica Ltd, H1 2017
  • Cystic Fibrosis - Pipeline by Novabiotics Ltd, H1 2017
  • Cystic Fibrosis - Pipeline by Novartis AG, H1 2017
  • Cystic Fibrosis - Pipeline by OSE Immunotherapeutics, H1 2017
  • Cystic Fibrosis - Pipeline by Paranta Biosciences Ltd, H1 2017
  • Cystic Fibrosis - Pipeline by Parion Sciences Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Pfizer Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Pharmaxis Ltd, H1 2017
  • Cystic Fibrosis - Pipeline by PhaseBio Pharmaceuticals Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Polyphor Ltd, H1 2017
  • Cystic Fibrosis - Pipeline by Progenra Inc, H1 2017
  • Cystic Fibrosis - Pipeline by ProMetic Life Sciences Inc, H1 2017
  • Cystic Fibrosis - Pipeline by ProQR Therapeutics NV, H1 2017
  • Cystic Fibrosis - Pipeline by Protalix BioTherapeutics Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Proteostasis Therapeutics Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Pulmatrix Inc, H1 2017
  • Cystic Fibrosis - Pipeline by RaNA Therapeutics Inc, H1 2017
  • Cystic Fibrosis - Pipeline by ReveraGen BioPharma Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Savara Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Shionogi & Co Ltd, H1 2017
  • Cystic Fibrosis - Pipeline by SOM Biotech SL, H1 2017
  • Cystic Fibrosis - Pipeline by Synedgen Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Synovo GmbH, H1 2017
  • Cystic Fibrosis - Pipeline by Vanda Pharmaceuticals Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Verona Pharma Plc, H1 2017
  • Cystic Fibrosis - Pipeline by Vertex Pharmaceuticals Inc, H1 2017
  • Cystic Fibrosis - Pipeline by Xenetic Biosciences Inc, H1 2017
  • Cystic Fibrosis - Dormant Projects, H1 2017
  • Cystic Fibrosis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Cystic Fibrosis - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Cystic Fibrosis - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Cystic Fibrosis - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Cystic Fibrosis - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Cystic Fibrosis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Cystic Fibrosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top